ConvaTec Appoints Paul Moraviec CEO Effective April 30, 2015


LUXEMBOURG (April 30, 2015) – ConvaTec, a privately-held medical products and technologies company, today announced that Paul Moraviec has been appointed Chief Executive Officer of the company.

Mr. Moraviec was appointed Interim CEO of ConvaTec in December 2014. “We are pleased to confirm Paul’s appointment as the CEO of ConvaTec,” said Magnus Lundberg, the Chairman of ConvaTec’s Board of Directors. “Over his six years with ConvaTec, Paul has built a successful business in Europe, and the company has performed well during his tenure as Interim CEO. We’re confident that, under his leadership, the company is well positioned for the future.”

“I look forward to working with the Board as the CEO of ConvaTec,” said Paul Moraviec. “I’m very excited about the future for our business and leading the company’s 9,000 employees in serving the patients, doctors and nurses who rely on us to help improve lives around the world.”

Mr. Moraviec joined ConvaTec in 2009 as President, Europe, Middle East and Africa, which is the company's largest geographic region. Mr. Moraviec has a track record of driving growth in major global healthcare companies across a number of medical device specialties including diabetes, neurosurgery, general surgery and orthopedics.

Mr. Moraviec has held international leadership roles with Johnson & Johnson, Abbott Laboratories and Bausch and Lomb, as well as CEO roles with two early-stage venture capital funded companies.

About ConvaTec

ConvaTec is a global medical products and technologies company, with leading market positions in wound therapeutics, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. ConvaTec has over 9,000 employees, with 11 manufacturing sites in 8 countries, and we do business in more than 100 countries. We are owned by Nordic Capital and Avista Capital Partners. More information is available at

# # #